Eli Lilly Invests Billions in Next-Generation Gene Therapy Platform
11.02.2026 - 22:01:04
While Eli Lilly continues to generate headlines and record earnings with its blockbuster weight-loss drugs, the pharmaceutical giant’s leadership is strategically deploying that capital. In a move valued at up to $2.4 billion, the company is acquiring Orna Therapeutics, a Massachusetts-based biotech firm, to gain a deep foothold in the evolving field of genetic medicine. The acquisition, announced on February 9th, aims to fundamentally simplify complex treatments for autoimmune conditions and broaden Lilly’s long-term portfolio.
This deal is part of a clear strategic initiative. Eli Lilly is leveraging the substantial revenue from its GLP-1 weight-loss business to reduce its dependence on any single therapeutic area. The financial capacity for such ambitious Read more...
@ boerse-global.de | US5324571083 ELI
